Equality and Human Rights Consultation - NICE TA - Everolimus with Exemestane for Treating Advanced Breast Cancer after Endocrine Therapy

Consultation opened on 10 November 2016. Closing date 21 December 2016.


NICE guidance is designed and developed for the NHS in England and is therefore not automatically applicable to Northern Ireland. On 1 July 2006 the Department established links with NICE whereby all technology appraisals and clinical guidelines published from that date are locally reviewed for applicability to Northern Ireland and, where appropriate, are endorsed for implementation in health and social care. THE LOCAL REVIEW DOES NOT REASSESS THE CLINICAL AND COST EVIDENCE USED BY NICE IN FORMING ITS ADVICE. This link has ensured that Northern Ireland has access to up-to-date, independent, professional, evidence-based guidance on the value of health care interventions.


Consultation description

Guidance for the consultation can be found on the NICE website.

The HSC (SQSD) 2/13 circular provides details of the process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland.

In order to meet the timescales set out in the circular, the closing date for responses is Wednesday 21st December 2016.

This will inform the Equality Screening

Share this consultation

Back to top